No Data
Shiyerjia (301371.SZ): It is expected that a new type II medical instrument product containing sodium hyaluronate will be launched this year.
Glory Holdings reported on January 8 that Fulejia (301371.SZ) recently stated in its investor relations activities that the company currently has sodium hyaluronate sub-packaged repair solution and anti-aging tightening sub-packaged essence available for sale. It is expected that this year, we will also launch a new sub-packaged solution with sodium hyaluronate ingredients, classified as a Class II medical instrument.
Shu Er Jia (301371.SZ): Currently, collagen products are positioned in both the medical instruments and Cosmetic categories.
Gelonghui, January 8th丨In a recent investor relationship activity, Fuyajia (301371.SZ) stated that the company currently has a presence in both the medical instruments and Cosmetic sectors with its collagen products. The collagen products in the medical instruments category available for sale include medical recombinant type III humanized collagen patches, which belong to class II medical instruments. Other products under research include class III medical instruments such as recombinant type III humanized collagen lyophilized fibers, injectable recombinant type III humanized collagen fillers, and recombinant type III humanized collagen dressings; within the Cosmetic category, the collagen products include collagen hydrating repair patches, collagen multi-effect repair patches, and collagen.
Shierjia (301371.SZ): Currently, the product matrix includes Class II medical instruments and functional skincare products, while also laying out Class III medical instruments.
On December 19, Gelonghui reported that Fulejia (301371.SZ) stated in a recent investor relations activity that the Industry represented a trend of refined demand and growing interest. Currently, Fulejia's product matrix includes Class II medical instruments and functional skincare products, while also developing Class III medical instruments. In the future, Fulejia will fully understand the competitive landscape, leveraging its advantages from the pharmaceutical industry to achieve high-quality growth as a premise and based on integrated marketing theory for sustainable development.
Furja (301371.SZ): In November this year, the company chose to open the first offline store in the country at Harbin Taiping International Airport.
Gelonghui, December 19th丨Fu'erjia (301371.SZ) recently stated in an investor relations event that the company's offline Business primarily operates through a distribution model. Considering that airports are transportation hubs, the company chose to open the first offline store in the country at Harbin Taiping International Airport in November this year.
Fillerjia (301371.SZ): Three types of Class II medical devices are expected to be launched next year.
On December 19, the company Geloonghui (301371.SZ) recently stated in an investor relations activity that currently, three categories of Class II medical devices are expected to be available next year, which are sodium hyaluronate sub-injection solutions and two dressings consisting of sodium polyglutamate and trehalose. As for cosmetics, nothing has been confirmed yet. The company hopes to launch 5 to 10 new products annually, focusing mainly on cosmetics, and also aims to incubate 1 to 2 L products each year.
Fulejia (301371.SZ): Online mainly based on direct sales, accounting for over 90% of online share.
Glory Financial reported on December 19 that Firerim (301371.SZ) stated in a recent investor relations activity that the company currently categorizes its operations into online and offline. The online sales model includes three types: direct sales, distribution, and consignment, with direct sales being the primary model, accounting for over ninety percent of online sales; while the offline sales model mainly consists of distribution.